Ϫ8
-10 Ϫ7 M), the specific A 2A agonist 2-p-(2-carboxyethyl)phenylamino-5Ј-N-ethyl carboxamidoadenosine (CGS-21680) (10 Ϫ5 M) effectively suppressed the vasodilator response of adenosine and forskolin. These results suggest that adenosine-induced vasodilation in rat diaphragm microcirculation is mediated through the stimulation of A 2A receptors, which are coupled to adenylate cyclase activation and opening of the K ATP channel. blood flow; glibenclamide; laser Doppler flowmetry; skeletal muscle ADENOSINE HAS BEEN SHOWN to be a vasodilator in most vascular beds except the renal or placenta tissues (27) . The effector mechanisms underlying the biological action of adenosine are believed to be mediated by the specific receptors known as P 1 purinoceptors (10, 14) . At least four adenosine receptor subtypes are currently known: A 1 , A 2A , A 2B , and A 3 receptors (12) . All of these receptors are members of the G protein-coupled receptor family, which is tightly linked to adenylate cyclase (AC) (11) . A 1 and A 3 receptors mediate the inhibition of AC activity, and A 2 receptors enhance AC activity (11) . Both A 1 and A 2 receptors have been reported to contribute to the vasodilation effect of adenosine (14) .
The ATP-dependent potassium (K ATP ) channel has been shown to participate in adenosine-induced vasodilation (AIV) at least in some vascular beds (4, 14, 20, 23, 25, 26) . Evidence suggests that adenosine may act on A 1 receptors to produce vasodilation via activation of the K ATP channel (4, 23) . Stimulation of A 1 receptors leads to reduced AC activity, and reduced cAMP is unlikely to mediate vasodilation; thus an important consequence is that activation of the K ATP channel may be coupled to A 1 receptors by a pertussis toxin-sensitive G protein but is independent of the AC-cAMP pathway (27) . On the other hand, some reports indicate that AIV is mediated by A 2 receptors (13, (23) (24) (25) . As stimulation of the A 2 receptors leads to enhanced AC activity and increased cAMP levels, the K ATP channel may be opened through cAMP-dependent protein kinase (19) . In resting or contracting skeletal muscles, adenosine produces vasodilation in a dose-dependent manner and is partly responsible for the development of functional hyperemia (6, 18) . The A 2 receptor is thought to be responsible for AIV in skeletal muscle (27) .
The mechanism by which adenosine modulates blood flow in the diaphragmatic vascular bed is a topic of considerable interest, because the diaphragm is the principle respiratory muscle. Because the microcirculation supplies nutrients to the tissue, understanding blood flow control in the diaphragm microvascular bed is of great importance. Danialou et al. (7) first described of the mechanisms of AIV on the rat diaphragm microcirculation under resting conditions using an intravital microscope. They concluded that activation of the A 1 receptor contributes to the vasodilation response of adenosine, but the A 2 receptor plays almost no role in this response. The K ATP channel and nitric oxide are also involved in the vasodilation process. The conclusions of Danialou et al. (7) contradict the conventional view that AIV in skeletal muscle is mediated via the A 2 receptor. The A 1 receptor predominantly contributes to vasodilation in skeletal muscle only under conditions of systemic hypoxia (3). Actually, Danialou's study is the only demonstration of the predominant role of A 1 receptors in AIV in the resting skeletal muscles. Laser Doppler flowmetry (LDF) has also been widely used to monitor microcirculatory blood flow (31) . In the present study, we used LDF in our previously developed rat diaphragm microcirculation model (5) to clarify the role of the K ATP channel and different adenosine receptors on AIV in rat diaphragm microcirculation. We first assessed the role of the K ATP channel-blocker glibenclamide on adenosine and adenosine agonist-induced vasodilation. Different adenosine antagonists were used to further elucidate the roles of each adenosine subtype on AIV. Finally, the role of AC in AIV was evaluated.
METHODS
Animal preparation. Male Sprague-Dawley rats (age 8-10 wk, weight 300-400 g) were housed at the Laboratory Animal Center of the College of Medicine at National Cheng Kung University. All animals were acclimatized to a 12:12-h light-dark cycle and were maintained on Purina Rat chow and tap water ad libitum. The animals were fasted overnight but allowed free access to water the day before the experiment.
The animals were initially anesthetized with pentobarbital sodium (30 mg/kg ip) followed by 50% wt/vol urethan (1.2-1.5 g/kg iv) and placed in a supine position on a rodent operating table (Harvard Apparatus, South Natick, MA). After a tracheostomy with polyethylene (PE)-240 tubing, muscle relaxant (gallamine triethiodide, 60 mg/kg) was administered and the rats were artificially ventilated at tidal volumes of 6-7 ml/kg and a rate of 70-80 breaths/min (model 683, Harvard Apparatus). The adequacy of ventilation was monitored with the aid of a micro CO 2 analyzer (model JS-02262, Polaris, Jerusalem, Israel) through a T-shaped connection to the tracheostomy tube. The end-tidal PCO 2 was maintained at 35-40 mmHg. Supplemental O 2 was applied to the inspiratory port at a fractional concentration of 40% (the balance being air). Mean systemic blood pressure (P SYS ) was measured with a PE-50 catheter inserted via the right carotid artery and connected to a pressure transducer (model P23 XL, Viggo-Spectramed, Oxnard, CA). The system was filled with heparin/saline (10 IU/ml). A cardiotachometer (model 13-4615-66, Gould, Cleveland, OH) triggered by the pressure signal was used to monitor heart rate. Another PE-10 catheter was inserted into the left external jugular vein for administration of fluid and anesthetic. Normal saline (3-5 ml ⅐ h Ϫ1 ⅐ 100 g Ϫ1 ) was infused throughout the experiment via a peristaltic pump (MS-Reglo, Ismatec, Glattbrugg, Switzerland). Depth of anesthesia was evaluated hourly by applying pressure to a paw and observing changes in heart rate or blood pressure. When either changed by more than 10% of baseline values, a supplementary dose of urethan (50 mg iv) was administered. Rectal temperature was continuously monitored with a thermistor and maintained at 36-38°C using a heating lamp and a temperature-regulated bed (model 50-7129, Harvard Apparatus). Arterial blood gases and hematocrit (Hct SYS ) were determined using 200-and 80-l blood samples, respectively.
Diaphragm preparation. The techniques used for diaphragm preparation have been described in detail elsewhere (5) . Briefly, a thoracotomy was performed in the right fifth and sixth intercostal spaces, and a 1-2-cm segment of the right sixth rib was removed. The diaphragm was separated from the lungs and the mediastinal tissues. An ovoid-shaped stainless steel plate coated with white glossy acrylic was slipped behind the diaphragm to hold the left hemi-diaphragm flat. The plate was fixed to the operation table via a miniature ball-jointed clamp system (model 50-4373, Harvard Apparatus).
Midline and transverse abdominal incisions were made and the ligament between the liver and the central tendon was severed. With the animal in the Trendelenberg position, the upper abdominal wall was folded back and retracted. Abdominal viscera were immobilized by wrapping them with a plastic cast. Superfusion of bicarbonate-buffered Ringer solution over the abdominal side of the left hemidiaphragm was performed at a flow rate of 5 ml/min via a peristaltic pump (model MC-MS/CA/4/8, Ismatec) immediately after exposure. The solution was equilibrated with 5% CO 2 -95% N 2 . The temperature of the superfusing fluid was maintained at 37°C and monitored with a thermistor thermometer at the outlet (model 8110-20, Cole-Palmer Instruments, Chicago, IL). A side port connected with a syringe pump (model 55-3333, Harvard Apparatus) was set up for the administration of drugs. The infusion rate was set at 1% of the superfusing fluid rate to standardize the final concentration of test agents.
Laser Doppler flowmetry. A commercially available laser Doppler flowmetry monitor (Laserflo BPM 2 , Vasamedics, St. Paul, MN) equipped with a small-caliber probe (model P443-3) was used to measure microvascular flow rates. The signal from the LDF was output as a direct current (Q LDF , updated eight times per second). The time constant was set at 1 s.
LDF signals were recorded continuously in all experiments. The probe, held in an MM-3 micromanipulator (Narishigi Instruments, Tokyo, Japan), was placed perpendicular to the surface of the diaphragm with the probe tip just touching the water film of the superfusate on the surface of the diaphragm. A site on the left costal diaphragm without visible large vessels was chosen and confirmed by visualization with a long-working-distance stereoscopic zoom microscope (SMZ-1, Nikon, Tokyo, Japan). After stable readings were obtained, the probe was kept in the same fixed position for the duration of the experiments. An average reading time of 30 s was required to provide a stable signal that was independent of vasomotion. At the end of the experiments, the animals were killed with an intravenous injection of saturated potassium chloride. The postmortem signal was considered as biological zero and subtracted from the LDF values.
Drugs. Urethan, gallamine triethiodide, adenosine, glibenclamide, and forskolin were obtained from Sigma Chemical (St. . Glibenclamide and DPCPX were dissolved in DMSO (final concentration 0.1%) and NaOH (final concentration 0.0001 N). 8-p-SPT was dissolved in NaOH (final concentration 0.0001 N). Forskolin and MDL-12330A were dissolved in ethanol. CGS-21680, NECA, R-PIA, and ZM-241385 were dissolved in DMSO (final concentration Ͻ0.1%). Urethan was prepared in saline at a 50% wt/vol concentration.
Experimental protocols. Experiments were initiated after a 30-to 45-min stabilization period. Arterial blood gas and hematocrit were determined. The animals used in this study met the following criteria during the stabilization period: 1) P SYS Ͼ 80 mmHg; 2) pH 7.35-7.50 and PO 2 Ͼ 100 mmHg; 3) Hct SYS Ͼ 40%; 4) Q LDF showed a greater than twofold increase compared with baseline values after topical application of adenosine at 10 Ϫ4 M; and 5) no obvious hemorrhage in the muscle tissue under investigation. Ten series of experiments were performed. Each series of experiments was performed in six rats.
Series 1-4 assessed the role of K ATP channel blocker glibenclamide on adenosine and adenosine agonist-induced vasodilation response in rat diaphragm microcirculation. The vasodilation response of rat diaphragm microcirculation to adenosine ( M and 10 Ϫ4 M. After Q LDF returned to baseline, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a specific A 1 receptor antagonist was applied to the preparation at a concentration of 5 X10
Ϫ8 M for 15 min by continuous suffusion and the effects of adenosine at these concentrations were recorded again. DPCPX was continuously suffused during the tests. In the experiments of series 6, 8-p-SPT, a nonselective adenosine receptor antagonist was used at a concentration of 3 ϫ 10
Ϫ5
M. In series 7, ZM-241385, a selective A 2A -receptor antagonist, was used at a concentration of 10 Ϫ6 M. In series 8 and 9, either no agent or vehicle (DMSO at a final concentration of 0.1% ϩ 0.0001 N NaOH) were used as suffusing agents (time and vehicle control). In series 10, the role of AC on the AIV response in rat diaphragm microcirculation was assessed. The AC inhibitor MDL-12330A and the AC activator forskolin were used in this series. After a baseline recording was completed, adenosine at 10 Ϫ5 M, 3.2 ϫ 10 Ϫ5 M, and 10 Ϫ4 M, and forskolin at 2 ϫ 10 Ϫ6 M were sequentially suffused to the preparation. After Q LDF had returned to baseline levels, MDL-12330A at 10
Ϫ5 M was applied topically for 15 min and a second run of adenosine and forskolin at the same concentrations was done after MDL-12330A was stopped.
Data acquisition and statistical analysis. P SYS and Q LDF inputs were fed into the chart recorder (Gould RS 3200 polygraph) for continuous recording. The output of pressure signals, heart rate, and the analog output from the LDF were directed into a multichannel analog interphase unit, where the data were sampled at 10 Hz with a 12-bit analog-todigital converter (AT codas, Dataq Instrument, Akron, OH) and stored in a personal computer. Recording periods complicated by artifacts were excluded before data analysis. The average LDF signal during a recording time of 30 s was defined as one measurement.
Results are expressed as means Ϯ SE. Responses to adenosine, forskolin, R-PIA, CGS-21680, and NECA were measured as a stable increase in Q LDF and expressed as a percentage of baseline values. Baseline Q LDF immediately before the start of suffusion with adenosine, forskolin, R-PIA, CGS-21680, and NECA represented 100% values for calculation of the percentage of the maximal change in Q LDF . Differences in mean values between groups were analyzed for statistical significance using two-way repeated-measures ANOVA. Differences in mean values among groups were analyzed for statistical significance using one-way repeated-measure ANOVA followed by Student's t-test with Bonferroni correction if necessary. When appropriate, Student's t-test for paired data was also used. A probability value of P Ͻ 0.05 was considered statistically significant. The number of observations (measurements) was denoted by n.
RESULTS

Systemic and microcirculatory variables.
The results are based on experiments carried out on 60 rats that met the inclusion criteria for P SYS , arterial blood gases, and Hct SYS . P SYS was 99.6 Ϯ 9.3 mmHg. The heart rate was 406 Ϯ 3.7 beats/min. Arterial pH was 7.41 Ϯ 0.01, arterial PO 2 was 133.9 Ϯ 3.1 mmHg, and arterial PCO 2 was 35.6 Ϯ 0.4 mmHg. Hct SYS was 45.6 Ϯ 0.3. The resting rate for Q LDF was 297.0 Ϯ 8.2 mV. No significant differences were found in baseline P SYS , heart rate, and Q LDF among animals in the 10 experimental groups as shown in Table 1 (P ϭ 0.152, 0.192, and 0.358, respectively). Eight typical tracings from each series of experiments are shown in Fig. 1 . Figure 2 illustrates that adenosine and several adenosine agonists elicited significant vasodilation responses in a dosedependent manner. All of these drugs elicited a similar degree of incremental microcirculatory flow (P Ͼ 0.05) under the different ranges of concentration used in this study. As shown in Fig. 2 , CGS-21680 and NECA elicited similar degrees of vasodilation using concen- trations 10 times lower than R-PIA. The vasodilation response induced by all of these drugs could be significantly inhibited by pretreatment with the K ATP channel blocker glibenclamide (3.2 ϫ 10 Ϫ6 M). Selectivity of adenosine receptor antagonist. Figure 3 shows that the vasodilation response elicited by incremental concentrations of adenosine was not blocked by DPCPX, yet 8-p-SPT and ZM-241385 significantly attenuated the AIV response. In the time and vehicle control groups, the vasodilation response induced by incremental concentrations of adenosine remained the same throughout the experiments (P Ͼ 0.05, data not shown). Figure 4 shows that the vasodilation response elicited by incremental concentrations of adenosine or with a single concentration of forskolin could be significantly attenuated by pretreatment of MDL-12330A for 15 min.
Effect of K ATP channel on adenosine and adenosine agonist-induced vasodilation response.
Effects of AC inhibitor MDL-12330A on adenosineand forskolin-induced vasodilation responses.
DISCUSSION
Although adenosine is known to be an important skeletal muscle vasodilator, only one study has provided information regarding its mechanism of action in diaphragm microcirculation (7). The results of the present study suggest that AIV in diaphragm microcirculation is mediated via binding of the A 2A receptor, which is coupled to AC stimulation and opening of the K ATP channel. However, our finding of adenosine subtype involvement in AIV in this vascular bed is in disagreement with the finding of Danialou et al. (7) . Classification of purinoceptors has been based on a combination of structural and pharmacological information (17) . At least four adenosine purinoceptors are known and have been cloned, i.e., A 1 , A 2A , A 2B , and A 3 , and all of them are coupled to guanine nucleotide binding proteins (11) . The availability of adenosine agonists has enabled differentiation among individual subtypes (14, 17) . A number of adenosine agonists exist with different individual subtype potencies (10, 14) . NECA is a nonselective agonist with high potency at A 1 (dissociation constant K i ϭ 6.3 nM), A 2A (K i ϭ 10.3 nM), and A 2B (K i ϭ 2 m). In this study, nanomolar ranges (10-100 nM) of NECA elicited an increase in diaphragmatic microcirculatory flow in a dose-dependent manner. Because a high concentration of NECA (micromolar range) is required for stimulation of the A 2B receptor (8) , it seems unlikely that the A 2B receptor is the adenosine subtype responsible for NECA-induced vasodilation. CGS-21680 is a selective agonist with high potency at the A 2A receptor (K i ϭ 15 nM), but low potency at the A 1 receptor (K i ϭ 2.6 M), and CGS-21680 elicited a similar degree of increase in diaphragmatic microcirculatory flow in a dose-dependent manner using the same concentrations as in the experiments with NECA. These findings suggest that the density of the A 2A receptor is abundant in this vascular bed.
R-PIA is an agonist with high potency at the A 1 receptor (K i ϭ 1.2 nM) and intermediate potency at the A 2 receptor (K i ϭ 124 nM) (14) . In this study, R-PIA also elicited similar degrees of incremental diaphragmatic microcirculatory flow using a concentration 10 times higher (100 nM to 1 M) than NECA or CGS-21680. In human pulmonary arteries or guinea pig coronary vasculature where the A 2 receptor was known to mediate AIV, R-PIA was found to elicit a doserelaxation curve similar to NECA with an agonist concentration 10 times higher (22, 32) . Therefore, the concentration of R-PIA used could also increase microcirculatory flow via the A 2 receptor. These findings suggest that AIV in this vascular bed is most likely mediated by the A 2A receptor. This result is also compatible with recent studies on rat or cat hindlimb vasculature, where the A 2A receptor was shown to mediate AIV or contribute to functional hyperemia (3, 28) .
To further clarify the issue of adenosine subtype involvement in AIV, several adenosine antagonists with different potencies at individual subtypes were used (10, 29) . DPCPX is a selective A 1 -receptor antagonist exhibiting 700-fold selectivity for the A 1 over the A 2 receptor (2). At a concentration of ϳ50 nM, DPCPX has been shown to be highly selective for A 1 -receptor antagonism and without effect on the A 2 receptor (2, 23, 32) . However, in this study, DPCPX (50 nM) failed to attenuate AIV, which suggests that AIV in this vascular bed is unlikely to be mediated via the A 1 receptor. 8-p-SPT is a nonselective antagonist that blocks both the A 1 and A 2 receptors. Although 8-p-SPT is regarded as a low-potency A 2 -receptor antagonist (10), it acts as an effective antagonist to the A 2 receptor at a concentration of 30 M (32). In this study, AIV in diaphragm microcirculation was significantly attenuated by 8-p-SPT, suggesting that the A 2 receptor is involved in AIV. Moreover, ZM-241385, a nonxanthine adenosinereceptor antagonist, exhibiting at least 100-fold higher affinity at the A 2A receptor than at the A 2B receptor, 1,000-fold lower affinity at the A 1 receptor, and 500,000-fold lower affinity at the A 3 receptor (28, 29) , was used for further discrimination. It has been reported that an intravenous dose of ZM-241385 up to 2 mg/kg produced only inhibition of the A 2A -adenosine receptor in dog hindlimb vasculature (28) . Therefore, ZM-241385 at a concentration of 1 M, which is much less than 2 mg/kg, should inhibit only the A 2A receptor in the rat diaphragmatic microvasculature. In this study, AIV in diaphragm microcirculation was also significantly blunted by ZM-241385, suggesting that the A 2A receptor is involved in AIV. As the A 3 receptor has been characterized as being resistant to blockade by 8-p-SPT or ZM-241385 and as having an equal agonist potency profile for R-PIA and NECA (16, 29) , it is unlikely to be involved in AIV of this vascular bed. Therefore, antagonist studies have also favored a predominant role of the A 2A receptor in mediating AIV response in rat diaphragm microvasculature.
The AC system is the most extensively studied effector system coupled to the adenosine receptor (14) . In rabbit mesenteric arterial myocytes, activation of AC results in increased intracellular cAMP levels, which can regulate phosphorylation of myosin light chain kinase by cAMP-dependent protein kinase with subsequent vasodilation (19) . MDL-12330A, an AC inhibitor (30) , was used in this study to test the hypothesis of AC involvement in AIV in the diaphragm. After administration of 10 M MDL-12330A, AIV was significantly attenuated, suggesting decreased AIV is mediated via inhibition of AC. This result was further supported by the inhibitory effect of MDL-12330A on forskolin, an AC activator, which induced vasodilation in diaphragm vascular bed. These findings indicate that activation of AC is involved in the AIV.
The involvement of the K ATP channel in AIV varies in different vascular preparations. The K ATP channel appears to be involved in AIV of rat hindlimb vasculature (4) or guinea pig coronary artery (25) but not in rat pulmonary circulation (16) or porcine epicardial vessels (21) . In this study, adenosine and vasodilation induced by the adenosine agonists NECA, CGS-21680, and R-PIA could be significantly blunted by pretreatment with the K ATP channel blocker glibenclamide, suggesting that the K ATP channel is at least partly responsible for AIV in the rat diaphragm vascular bed.
The results obtained from the present study are in contrast with a recent study of AIV in rat diaphragm microcirculation. Using an intravital microscope, Danialou et al. (7) concluded that AIV in rat diaphragm microcirculation was mediated predominantly via the A 1 receptor. This discrepancy could have several explanations. First, the measuring instrument and anesthetics used were different in these two studies. In this study, we mainly used urethan for general anesthesia; however, in Danialou's study only pentobarbital sodium was used. Second, differences in the spatial variation of the diaphragm vascular bed may have involved different mechanisms of AIV in different sized arterioles (9, 15) . Only diameter changes of the superficial arterioles were reported in Danialou's study due to limitations of the intravital microscope (1), but the measurement by LDF consists mostly of capillary flow. Therefore, discrepancies in the results of our study may have been due to different sites of measurement. A third possible explanation for the discrepancy may be related to the inclusion criteria used to select rats for study. In Danialou's study, no inclusion criteria were mentioned; however, in our study strict inclusion criteria were used to ensure appropriate hemodynamic and oxygenation status of the rats. It is known that activation of the A 1 receptor contributes predominantly to AIV in rat limb muscles during systemic hypoxia (3).
In conclusion, we have provided functional evidence that the predominant mechanism of AIV in resting rat diaphragm microcirculation is mediated via stimulation of the A 2A receptor. The binding of adenosine to the A 2A receptor is coupled to the activation of AC and the opening of the K ATP channel. This information may be valuable in respiratory muscle pathophysiology because the diaphragm is the principal respiratory muscle.
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